NDAPERIARTICULARSOLUTION, EXTENDED RELEASEPriority Review
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
ZYNRELEF KIT (bupivacaine and meloxicam) by Heron Therapeutics is cyclooxygenase inhibitors [moa]. First approved in 2021.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYNRELEF KIT is a fixed-dose combination of bupivacaine (local anesthetic) and meloxicam (NSAID) formulated as an extended-release periarticular solution. It is indicated for pain management in patients undergoing joint surgery, delivering both local anesthesia and anti-inflammatory benefit at the surgical site. The combination leverages cyclooxygenase inhibition to reduce inflammation while providing prolonged local anesthetic coverage.
Peak9.8 years to LOE
Product is at peak commercial maturity with established market penetration; brand teams are focused on market defense and optimization rather than growth investment.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZYNRELEF represents a stable, peak-stage commercial product within a specialized surgical pain management niche; roles are weighted toward commercial execution, market access, and healthcare provider education rather than clinical development. Working on this product offers visibility into specialty orthopedic markets and perioperative decision-making, but limited exposure to early-stage innovation or pipeline advancement.
Brand Manager
Worked on ZYNRELEF KIT at Heron Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.